# Chemo-free BRCA-targeted Neoadjuvant Strategy

> **NCT05209529** · PHASE2 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- TNBC - Triple-Negative Breast Cancer
- BRCA1 Mutation
- BRCA2 Mutation

## Interventions

- **DRUG:** olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05209529
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-02-01
- **Primary completion:** 2028-09-06
- **Final completion:** 2030-07-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn interest from grant provider
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05209529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05209529, "Chemo-free BRCA-targeted Neoadjuvant Strategy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05209529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*